PMID- 21423295
OWN - NLM
STAT- MEDLINE
DCOM- 20120213
LR  - 20171116
IS  - 1205-7541 (Electronic)
IS  - 0008-4212 (Linking)
VI  - 89
IP  - 3
DP  - 2011 Mar
TI  - Modulation of metabolic and cardiac dysfunctions by insulin sensitizers and 
      angiotensin receptor blocker in rat model of type 2 diabetes mellitus.
PG  - 216-26
LID - 10.1139/Y11-012 [doi]
AB  - The objective of this study was to investigate the modulation of metabolic 
      dysfunctions, adiponectin levels, and cardiac dysfunctions of type 2 diabetes 
      mellitus (T2DM) by a combination of the insulin sensitizer rosiglitazone and 
      angiotensin receptor blocker telmisartan in an experimental rat model. Fifty male 
      adult Sprague-Dawley rats were divided equally into 5 groups. Group I: fed normal 
      chow; served as normal control group. Groups II-V: fed a high-fat diet (HFD) for 
      2 weeks, followed by injection of streptozotocin (STZ; 35 mg/kg) to create a 
      model of T2DM. Group II: treated with vehicle. Group III: treated with 
      rosiglitazone (4 mg/kg). Group IV: treated with telmisartan (5 mg/kg). Group V: 
      treated with both agents. Untreated HFD-STZ rats showed elevated fasting blood 
      glucose, insulin, homeostasis model assessment (HOMA) index, triglycerides (TGs), 
      low-density lipoprotein cholesterol (LDL), and total serum cholesterol (TC), with 
      a decrease in high-density lipoprotein cholesterol (HDL) and adiponectin levels 
      (p < 0.001). Rosiglitazone exerted more improvement in all parameters than 
      telmisartan did, and a combination of both did not augment the improvement 
      further, except for TGs and adiponectin. For the isolated atrial study, a 
      combination of rosiglitazone and telmisartan corrected the responses of the atria 
      of HFD-STZ rats to the negative inotropic effect induced by adenosine better than 
      either one did alone, whereas this combination, surprisingly, significantly 
      attenuated the positive inotropic response to beta-adrenoreceptor and 
      alpha-adrenoreceptor agonists. In conclusion, rosiglitazone significantly improved 
      the metabolic and cardiac dysfunctions in T2DM. Moreover, a combination of 
      rosiglitazone and telmisartan offered more improvement in serum TGs and 
      adiponectin, and restored the atrial inotropic response to adenosine. 
      Surprisingly, this combination significantly attenuates the positive inotropic 
      response to alpha1-adrenoreceptor and beta-adrenoreceptor agonists.
FAU - Hussein, Abd El-Aziz M
AU  - Hussein Ael-A
AD  - Department of Medical Physiology, Faculty of Medicine, Mansoura University, 
      Egypt. zizomenna@yahoo.com
FAU - Omar, Nisereen M
AU  - Omar NM
FAU - Sakr, Hussein
AU  - Sakr H
FAU - Elsamanoudy, Ayman Z
AU  - Elsamanoudy AZ
FAU - Shaheen, Dalia
AU  - Shaheen D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Canada
TA  - Can J Physiol Pharmacol
JT  - Canadian journal of physiology and pharmacology
JID - 0372712
RN  - 0 (Adiponectin)
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Biomarkers)
RN  - 0 (Insulin)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Adiponectin/blood
MH  - Angiotensin Receptor Antagonists/*therapeutic use
MH  - Animals
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/*blood/drug therapy/physiopathology
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy/physiopathology
MH  - *Disease Models, Animal
MH  - Insulin/analogs & derivatives/*therapeutic use
MH  - Male
MH  - Metabolic Syndrome/*blood/drug therapy/physiopathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Triglycerides/blood
EDAT- 2011/03/23 06:00
MHDA- 2012/02/14 06:00
CRDT- 2011/03/23 06:00
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2012/02/14 06:00 [medline]
AID - y11-012 [pii]
AID - 10.1139/Y11-012 [doi]
PST - ppublish
SO  - Can J Physiol Pharmacol. 2011 Mar;89(3):216-26. doi: 10.1139/Y11-012.